Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

Every woman’s journey is unique. Understanding how the body prepares for ovulation is crucial to improving one's chances of conception. A follicular study, also known as follicular monitoring, helps ...

Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of ...

Patients with high-risk relapsed/refractory follicular lymphoma experienced statistically significant and clinically meaningful responses when treated with lisocabtagene maraleucel (liso-cel; Breyanzi ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...